Lingyun Ye

Halifax, NS, Canada

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 40 publications

A controlled human infection model for symptomatic pertussis in North America using the pertactin-producing clinical isolate D420.

A controlled human infection model for symptomatic pertussis in North America using the pertactin-producing clinical isolate D420.

Journal: medRxiv : the preprint server for health sciences
Published: June 29, 2026

Safety and immunogenicity of one or two doses of the rVSVΔG-ZEBOV-GP Ebola virus vaccine in adults and adolescents living with HIV: a phase 2, multicentre, double-blind, randomised, placebo-controlled trial.

Safety and immunogenicity of one or two doses of the rVSVΔG-ZEBOV-GP Ebola virus vaccine in adults and adolescents living with HIV: a phase 2, multicentre, double-blind, randomised, placebo-controlled trial.

Journal: The lancet. HIV
Published: February 25, 2026

Healthcare providers' awareness, attitudes, beliefs, and practices surrounding pharmacist-administered vaccination: Insights after a two-year intervention.

Healthcare providers' awareness, attitudes, beliefs, and practices surrounding pharmacist-administered vaccination: Insights after a two-year intervention.

Journal: Human vaccines & immunotherapeutics
Published: January 06, 2026

Safety and immunogenicity of a 25-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive healthy adults: Results from 2 randomised, controlled clinical trials.

Safety and immunogenicity of a 25-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive healthy adults: Results from 2 randomised, controlled clinical trials.

Journal: Vaccine
Published: November 18, 2025

Adenovirus type 5 vector-based COVID-19 vaccine does not increase the likelihood of HIV infection.

Adenovirus type 5 vector-based COVID-19 vaccine does not increase the likelihood of HIV infection.

Journal: Vaccine
Published: October 09, 2025

Relative efficacy, safety, and immunogenicity analysis of two doses versus one dose of recombinant coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomized, double blinded phase 3 trial.

Relative efficacy, safety, and immunogenicity analysis of two doses versus one dose of recombinant coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomized, double blinded phase 3 trial.

Journal: Vaccine
Published: August 25, 2025

Safety and immunogenicity of COVAC-2, a Sepivac SWE™ adjuvanted SARS-CoV-2 recombinant protein vaccine in healthy adults; a randomized controlled first-in-human dose-escalation trial.

Safety and immunogenicity of COVAC-2, a Sepivac SWE™ adjuvanted SARS-CoV-2 recombinant protein vaccine in healthy adults; a randomized controlled first-in-human dose-escalation trial.

Journal: Vaccine
Published: July 30, 2025

The impact of two-year community-wide pharmacy interventions on the public's knowledge, attitudes, beliefs and behaviors about pharmacists as immunizers.

The impact of two-year community-wide pharmacy interventions on the public's knowledge, attitudes, beliefs and behaviors about pharmacists as immunizers.

Journal: BMC public health
Published: March 06, 2025

Increased Respiratory Syncytial Virus-Associated Hospitalizations and Ambulatory Visits in Very Preterm Infants in the First Year of Life following Discontinuation of Access to Palivizumab.

Increased Respiratory Syncytial Virus-Associated Hospitalizations and Ambulatory Visits in Very Preterm Infants in the First Year of Life following Discontinuation of Access to Palivizumab.

Journal: American journal of perinatology
Published: January 09, 2025

Oseltamivir Reduces 30-Day Mortality in Older Adults With Influenza: A Pooled Analysis From the 2012-2019 Serious Outcomes Surveillance Network of the Canadian Immunization Research Network.

Oseltamivir Reduces 30-Day Mortality in Older Adults With Influenza: A Pooled Analysis From the 2012-2019 Serious Outcomes Surveillance Network of the Canadian Immunization Research Network.

Journal: Open forum infectious diseases
Published: December 11, 2024

An enveloped virus-like particle alum-adjuvanted cytomegalovirus vaccine is safe and immunogenic: A first-in-humans Canadian Immunization Research Network (CIRN) study.

An enveloped virus-like particle alum-adjuvanted cytomegalovirus vaccine is safe and immunogenic: A first-in-humans Canadian Immunization Research Network (CIRN) study.

Journal: Vaccine
Published: August 14, 2023

Vaccine Effectiveness of non-adjuvanted and adjuvanted trivalent inactivated influenza vaccines in the prevention of influenza-related hospitalization in older adults: A pooled analysis from the Serious Outcomes Surveillance (SOS) Network of the Canadian Immunization Research Network (CIRN).

Vaccine Effectiveness of non-adjuvanted and adjuvanted trivalent inactivated influenza vaccines in the prevention of influenza-related hospitalization in older adults: A pooled analysis from the Serious Outcomes Surveillance (SOS) Network of the Canadian Immunization Research Network (CIRN).

Journal: Vaccine
Published: June 15, 2023
Showing 1-12 of 40

Last Updated: 09/26/2026